Piramal Pharma has reported total income of Rs. 2,302.86 crores during the period ended September 30, 2024
Company receives acceptability, in principle, for ZyVac TCV making it eligible for purchase by United Nations procurement agencies
Extension of long-term collaboration includes construction of new customer-dedicated bioconjugation capacity in Visp (CH) and commercial antibody supply of a new ADC
He has more than 25 years of experience in manufacturing across various industries including petrochemicals, engineering polymers, agrochemicals, organic, and inorganic intermediates
Solara Active Pharma Sciences has reported total income of Rs. 347.27 crores during the period ended September 30, 2024
ActivShield technology is a portable, novel sterilization modality that does not require conventional infrastructure
This partnership will enable healthcare organizations to provide best-in-class patient/consumer experiences
Financing includes new funding from leading global organizations Eli Lilly and Company and EDBI
The proceeds from its fresh issuance to the extent of Rs 107 crore will be utilized for funding the capital expenditure requirements
Subscribe To Our Newsletter & Stay Updated